Simultaneous presentation of low-and middle-income countries data for hematologic cancers: a welcome step towards equity


  • Suvir Singh Department of Clinical Hematology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India



Advances in cancer treatment over the last few decades have been nothing short of remarkable, and have led to significant improvements in survival and quality of life.This has been possible with several noticeable changes such as discovery of molecular mechanisms of cancer, targeted drug development, and better laboratory methods. However, a majority of this benefit is confined to high income countries (HICs), and international disparities are still widely prevalent. Several unique socioeconomic, environmental and political challenges preclude emulation of new developments in the LMIC (low-and middle-income countries) settings.


Metrics Loading ...


Tehranifar P, Neugut AI, Phelan JC, Link BG, Liao Y, Desai M et al. Medical advances and racial/ethnic disparities in cancer survival. Cancer Epidemiol Prevention Biomarkers. 2009;18(10):2701-8.

Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang X-S et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977-1010.

Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010;376(9747):1186-93.

Turkina A, Wang J, Mathews V, Saydam G, Jung CW, Al Hashmi HH et al. TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries. Bri J Haematol. 2020;190(6):869-76.

Hokland P, Shah M, David K, Evens A, Auer R, Ledieu R et al. How I treat advanced Hodgkin lymphoma-a global view. Bri J Haematol. 2020;190(6):837-50.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer J clin. 2018;68(6):394-424.

Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends-An Update. Cancer Epidemiol Biomarkers amp; Prevention. 2016;25(1):16-27.

Curado MP, Voti L, Sortino-Rachou AM. Cancer registration data and quality indicators in low and middle income countries: their interpretation and potential use for the improvement of cancer care. Cancer Causes Control. 2009;20(5):751-6.

Wilson C, Tobin S, Young R. The exploding worldwide cancer burden. Int J Gynecol Cancer. 2004;14:1.

Singh GK, Jemal A. Socioeconomic and Racial/Ethnic Disparities in Cancer Mortality, Incidence, and Survival in the United States, 1950-2014: Over Six Decades of Changing Patterns and Widening Inequalities. J Environ Public Health. 2017;2017:2819372.

Heneghan C, Blacklock C, Perera R, Davis R, Banerjee A, Gill P et al. Evidence for non-communicable diseases: analysis of Cochrane reviews and randomised trials by World Bank classification. BMJ open. 2013;3:7.

Phan VH, Tan C, Rittau A, Xu H, McLachlan AJ, Clarke SJ. An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. Expert opinion drug metabolism toxicol. 2011;7(11):1395-410.

Beran D, Byass P, Gbakima A, Kahn K, Sankoh O, Tollman S et al. Research capacity building 2014;obligations for global health partners. Lancet Global Health. 2017;5(6):e567-e8.

Sharma SK, Choudhary D, Gupta N, Dhamija M, Khandelwal V, Kharya G et al. Cost of hematopoietic stem cell transplantation in India. Mediterranean J Hematol Infect Dis. 2014;6:1.

Bajel A, George B, Mathews V, Viswabandya A, Kavitha ML, Srivastava A et al. Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol. Pediatr Blood Cancer. 2008;51(5):621-5.

Malhotra P, Yanamandra U, Khadwal A, Prakash G, Lad D, Law AD et al. Autologous stem cell transplantation for multiple myeloma: single centre experience from North India. Indian J Hematol Blood Transfusion. 2018;34(2):261-7.






Letter to the Editor